Denali Therapeutics Inc. (NASDAQ:DNLI - Get Free Report) Director Vicki L. Sato sold 1,666 shares of the company's stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the sale, the director now owns 118,043 shares in the company, valued at approximately $2,159,006.47. The sale was disclosed in a filing with the SEC, which is available through the SEC website.
Denali Therapeutics Price Performance
NASDAQ DNLI opened at $16.82 on Thursday. The firm's fifty day moving average price is $19.27 and its 200 day moving average price is $19.27. Denali Therapeutics Inc. has a 12 month low of $15.45 and a 12 month high of $33.31. The company has a market capitalization of $2.34 billion, a price-to-earnings ratio of -15.57 and a beta of 1.33.
Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The company reported ($0.86) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by ($0.05). Denali Therapeutics had a negative return on equity of 13.50% and a negative net margin of 36.51%. During the same period in the previous year, the business posted ($0.75) EPS. As a group, sell-side analysts forecast that Denali Therapeutics Inc. will post -2.62 earnings per share for the current year.
Institutional Inflows and Outflows
Biden to Launch “FedNOW” [Move Your Money Now]
From Priority Gold | Ad
Earlier this year President Biden signed the death warrant for America…
Executive Order 14067 will essentially cancel your money.
You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...
Get your free information kit NOW, before it's too late.
Institutional investors have recently added to or reduced their stakes in the company. CWM LLC grew its position in shares of Denali Therapeutics by 216.7% during the fourth quarter. CWM LLC now owns 2,011 shares of the company's stock worth $43,000 after acquiring an additional 1,376 shares during the last quarter. Assetmark Inc. boosted its stake in Denali Therapeutics by 49.1% during the 3rd quarter. Assetmark Inc. now owns 2,148 shares of the company's stock worth $44,000 after purchasing an additional 707 shares during the period. PNC Financial Services Group Inc. grew its position in Denali Therapeutics by 85.2% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company's stock worth $46,000 after purchasing an additional 768 shares during the last quarter. KBC Group NV purchased a new position in Denali Therapeutics during the 4th quarter worth $53,000. Finally, Fisher Asset Management LLC acquired a new position in Denali Therapeutics in the fourth quarter valued at $59,000. Institutional investors and hedge funds own 92.92% of the company's stock.
Analyst Ratings Changes
A number of analysts recently weighed in on the stock. The Goldman Sachs Group cut their target price on shares of Denali Therapeutics from $73.00 to $50.00 and set a "buy" rating on the stock in a research note on Thursday, February 29th. Wedbush reissued an "outperform" rating and issued a $31.00 price objective on shares of Denali Therapeutics in a research report on Wednesday, February 28th. HC Wainwright decreased their price objective on shares of Denali Therapeutics from $105.00 to $95.00 and set a "buy" rating for the company in a research report on Wednesday, February 28th. Finally, UBS Group lowered their target price on shares of Denali Therapeutics from $70.00 to $32.00 and set a "buy" rating for the company in a research note on Tuesday, April 9th. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $41.22.
Get Our Latest Stock Analysis on DNLI
About Denali Therapeutics
(
Get Free Report)
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
